Johnston B L, Kwok R Y, Mulligan M E
Medical Service, V.A. West Los Angeles Medical Center, California.
Diagn Microbiol Infect Dis. 1987 Nov;8(3):137-47. doi: 10.1016/0732-8893(87)90164-7.
Rifampin and novobiocin both have excellent activity against oxacillin-resistant Staphylococcus aureus, but their single use may be associated with the development of resistance. To help predict their clinical value in our institution, 60 recent clinical isolates of oxacillin-resistant S. aureus were studied for in vitro susceptibility to the two agents. Ten isolates with increased MICs to both agents or to rifampin alone were also studied by modified checkerboard and kill-curve methods. Indifference was consistently demonstrated by the checkerboard method and generally found in kill-curve studies. Prevention of development of resistance was demonstrated with the antimicrobial combinations for some isolates. Isolates with increased MICs for the two agents fell into two distinctive groups, with prevention of the development of rifampin resistance occurring in one group but not in the other, suggesting that different strains of oxacillin-resistant S. aureus may have different capacities for development of rifampin resistance.
利福平与新生霉素对耐苯唑西林金黄色葡萄球菌均有出色的抗菌活性，但单独使用它们可能会导致耐药性的产生。为了帮助预测它们在我们机构中的临床价值，我们对60株近期分离的耐苯唑西林金黄色葡萄球菌临床菌株进行了体外药敏试验，检测这两种药物对其的敏感性。另外，我们还采用改良棋盘法和杀菌曲线法，对10株对这两种药物或仅对利福平的最低抑菌浓度（MIC）升高的菌株进行了研究。棋盘法始终显示为无差异，杀菌曲线研究中通常也发现无差异。对于一些菌株，抗菌药物联合使用可防止耐药性的产生。对这两种药物MIC升高的菌株分为两个不同的组，其中一组可防止利福平耐药性的产生，而另一组则不能，这表明不同的耐苯唑西林金黄色葡萄球菌菌株产生利福平耐药性的能力可能不同。
